These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 18444846)

  • 21. [Pneumonia in ambulatory care patients. Choice of antibiotics for therapy of community-acquired pneumonia].
    Buchenroth M; Lorenz J
    Fortschr Med; 1998 Apr; 116(11):22-8, 30. PubMed ID: 9609921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clarithromycin in the management of community-acquired pneumonia.
    McCarty JM
    Clin Ther; 2000 Mar; 22(3):281-94; discussion 265. PubMed ID: 10963284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
    Pertel PE; Bernardo P; Fogarty C; Matthews P; Northland R; Benvenuto M; Thorne GM; Luperchio SA; Arbeit RD; Alder J
    Clin Infect Dis; 2008 Apr; 46(8):1142-51. PubMed ID: 18444848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?).
    Low DE
    Infect Dis Clin North Am; 2013 Mar; 27(1):87-97. PubMed ID: 23398867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A stochastic assessment of the public health risks of the use of macrolide antibiotics in food animals.
    Hurd HS; Malladi S
    Risk Anal; 2008 Jun; 28(3):695-710. PubMed ID: 18643826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis.
    Li JZ; Winston LG; Moore DH; Bent S
    Am J Med; 2007 Sep; 120(9):783-90. PubMed ID: 17765048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Community-acquired pneumonia: attitude case of treatment failure].
    Genné D; Rakotoarimanana R
    Rev Med Suisse; 2005 Oct; 1(36):2333-4, 2336-7. PubMed ID: 16281444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Short course antibiotherapies in community-acquired pneumonia].
    Bulbul Y; Ozlu T
    Tuberk Toraks; 2008; 56(3):344-52. PubMed ID: 18932039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia.
    Rosón B; Carratalà J; Fernández-Sabé N; Tubau F; Manresa F; Gudiol F
    Arch Intern Med; 2004 Mar; 164(5):502-8. PubMed ID: 15006826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy in pneumonia: what is beyond antibiotics?
    Meijvis SC; Grutters JC; Thijsen SF; Rijkers GT; Biesma DH; Endeman H
    Neth J Med; 2011 Jan; 69(1):21-6. PubMed ID: 21325697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Two guidelines on community-acquired pneumonia: both an important basis for individual policies].
    van den Broek PJ
    Ned Tijdschr Geneeskd; 2005 Nov; 149(45):2492-4. PubMed ID: 16304885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.
    File TM
    Clin Infect Dis; 2004 Sep; 39 Suppl 3():S159-64. PubMed ID: 15546111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
    Bratzler DW; Ma A; Nsa W
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.
    Tessmer A; Welte T; Martus P; Schnoor M; Marre R; Suttorp N
    J Antimicrob Chemother; 2009 May; 63(5):1025-33. PubMed ID: 19293196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
    Martin M; Moore L; Quilici S; Decramer M; Simoens S
    Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).
    Lavoie F; Blais L; Castilloux AM; Scalera A; LeLorier J
    Can J Clin Pharmacol; 2005; 12(2):e212-7. PubMed ID: 15998960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
    Rapp RP
    Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-acquired pneumonia.
    Yu KT; Wyer PC
    Ann Emerg Med; 2008 May; 51(5):651-62, 662.e1-2. PubMed ID: 18272253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early and late treatment failure in community-acquired pneumonia.
    Garcia-Vidal C; Carratalà J
    Semin Respir Crit Care Med; 2009 Apr; 30(2):154-60. PubMed ID: 19296415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Basis and guidelines for empirical antibody therapy in the management of community-acquired pneumonia].
    Louzir B; Beji M; Fajraoui N; Mehiri N; Daghfous J
    Tunis Med; 2001 Oct; 79(10):491-7. PubMed ID: 11910687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.